143 related articles for article (PubMed ID: 34441043)
41. Prognostic and Therapeutic Significance of Adhesion-regulating Molecule 1 in Estrogen Receptor-positive Breast Cancer.
Wu W; Zhong J; Chen J; Niu P; Ding Y; Han S; Xu J; Dai L
Clin Breast Cancer; 2020 Apr; 20(2):131-144.e3. PubMed ID: 31669266
[TBL] [Abstract][Full Text] [Related]
42. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.
Krishnamurti U; Wetherilt CS; Yang J; Peng L; Li X
Hum Pathol; 2017 Jun; 64():7-12. PubMed ID: 28153508
[TBL] [Abstract][Full Text] [Related]
43. Constitutive expression of γ-H2AX has prognostic relevance in triple negative breast cancer.
Nagelkerke A; van Kuijk SJ; Sweep FC; Nagtegaal ID; Hoogerbrugge N; Martens JW; Timmermans MA; van Laarhoven HW; Bussink J; Span PN
Radiother Oncol; 2011 Oct; 101(1):39-45. PubMed ID: 21840613
[TBL] [Abstract][Full Text] [Related]
44. Prognostic Significance of Androgen Receptor Expression in Triple Negative Breast Cancer: A Systematic Review and Meta-Analysis.
Xu M; Yuan Y; Yan P; Jiang J; Ma P; Niu X; Ma S; Cai H; Yang K
Clin Breast Cancer; 2020 Aug; 20(4):e385-e396. PubMed ID: 32139270
[TBL] [Abstract][Full Text] [Related]
45. Nuclear TAZ expression associates with the triple-negative phenotype in breast cancer.
Díaz-Martín J; López-García MÁ; Romero-Pérez L; Atienza-Amores MR; Pecero ML; Castilla MÁ; Biscuola M; Santón A; Palacios J
Endocr Relat Cancer; 2015 Jun; 22(3):443-54. PubMed ID: 25870251
[TBL] [Abstract][Full Text] [Related]
46. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis.
Gao ZH; Li CX; Liu M; Jiang JY
BMC Cancer; 2020 Nov; 20(1):1150. PubMed ID: 33238978
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of the Expression of Amine Oxidase Proteins in Breast Cancer.
Sun WY; Choi J; Cha YJ; Koo JS
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29261141
[TBL] [Abstract][Full Text] [Related]
48. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
49. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
50. Prognostic significance of LAPTM4B and p27kip1 expression in triple-negative breast cancer.
Li X; Song C; Wang K; Li N; Sun S; Li N; Zhao Z; Li M
Cancer Biomark; 2019; 25(1):19-27. PubMed ID: 31033460
[TBL] [Abstract][Full Text] [Related]
51. Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.
Jézéquel P; Loussouarn D; Guérin-Charbonnel C; Campion L; Vanier A; Gouraud W; Lasla H; Guette C; Valo I; Verrièle V; Campone M
Breast Cancer Res; 2015 Mar; 17():43. PubMed ID: 25887482
[TBL] [Abstract][Full Text] [Related]
52. Active behavior of triple-negative breast cancer with adipose tissue invasion: a single center and retrospective review.
Yamaguchi J; Moriuchi H; Ueda T; Kawashita Y; Hazeyama T; Tateishi M; Aoki S; Uchihashi K; Nakamura M
BMC Cancer; 2021 Apr; 21(1):434. PubMed ID: 33879104
[TBL] [Abstract][Full Text] [Related]
53. Differential expression of epithelial–mesenchymal transition and stem cell markers in intrinsic subtypes of breast cancer.
Pomp V; Leo C; Mauracher A; Korol D; Guo W; Varga Z
Breast Cancer Res Treat; 2015 Nov; 154(1):45-55. PubMed ID: 26467042
[TBL] [Abstract][Full Text] [Related]
54. Prolonged survival after diagnosis of brain metastasis from breast cancer: contributing factors and treatment implications.
Honda Y; Aruga T; Yamashita T; Miyamoto H; Horiguchi K; Kitagawa D; Idera N; Goto R; Kuroi K
Jpn J Clin Oncol; 2015 Aug; 45(8):713-8. PubMed ID: 25981620
[TBL] [Abstract][Full Text] [Related]
55. Triple-negative breast cancer: An institutional analysis.
Gogia A; Raina V; Deo SV; Shukla NK; Mohanti BK
Indian J Cancer; 2014; 51(2):163-6. PubMed ID: 25104201
[TBL] [Abstract][Full Text] [Related]
56. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
[TBL] [Abstract][Full Text] [Related]
57. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
[TBL] [Abstract][Full Text] [Related]
58. The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast.
Narbe U; Sjöström M; Forsare C; Bendahl PO; Alkner S; Leeb-Lundberg LMF; Lövgren K; Rydén L; Ingvar C; Fernö M
Breast Cancer Res Treat; 2019 Jun; 175(2):305-316. PubMed ID: 30796653
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of human epididymal secretory protein 4 expression according to the molecular subtypes (luminal A, luminal B, human epidermal growth factor receptor 2-positive, triple-negative) of breast cancer.
Akoz G; Diniz G; Ekmekci S; Ekin ZY; Uncel M
Indian J Pathol Microbiol; 2018; 61(3):323-329. PubMed ID: 30004048
[TBL] [Abstract][Full Text] [Related]
60. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.
Dieci MV; Mathieu MC; Guarneri V; Conte P; Delaloge S; Andre F; Goubar A
Ann Oncol; 2015 Aug; 26(8):1698-704. PubMed ID: 25995301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]